Efficacy of SEROQUEL in Selective Serotonin Reuptake Inhibitors (SSRI)-Resistant Major Depressive Disorder

An Open-Label, Non-Comparative, Multi-Centre, Phase II Prospective Trial to Assess the Efficacy of Quetiapine Fumarate Augmentation of Selective Serotonin Reuptake Inhibitors (SSRIs) in SSRI-Resistant Major Depressive Disorder.

An open-label, non-comparative, multi-centre, phase II prospective trial to assess the efficacy of Quetiapine fumarate augmentation of selective serotonin reuptake inhibitors (SSRIs) in SSRI-resistant major depressive disorder.

Inclusion Criteria:

• Inform consent
• Male and female, age between 18 and 65 years.
• Naïve to any atypical antipsychotic
• A diagnosis of major depressive disorder

Exclusion Criteria:

• No use of fluvoxamine
• Patients with a history of bipolar I or II disorder
• Diagnosis of psychotic major depression disorder